论文部分内容阅读
目的:探讨重组人生长激素(rhGH)治疗小于胎龄儿(SGA)矮小症患儿的疗效及适宜疗程。方法:将2009年12月至2011年12月收治的88例SGA矮小症患儿,分为治疗组34例和对照组54例。治疗组给予rhGH 0.15 U/(kg·d)治疗,并分别观察6个月、1年、1年6个月、2年疗程患儿身高的增长情况。结果:经2年观察,治疗组31例出现有效追赶生长,有效率达91.2%,对照组仅5例出现追赶生长,有效率9.3%(χ2=57.92 P<0.01)。rhGH不同疗程的疗效在总体上差异有统计学意义(χ2=33.58,P<0.01);除1年6个月疗程和2年疗程的疗效比较差异无统计学意义(χ2=0.57,P>0.05)外,其余不同疗程组间疗效比较差异均有统计学意义(P<0.05)。结论:rhGH能有效促进SGA矮小症患儿出现追赶生长,在每天0.15 U/kg的治疗剂量下,1年6个月疗程可使大部分患儿达到X-1SD~X正常身高区间,且1年6个月的疗程费用与效益比更高,是适宜疗程。
Objective: To investigate the therapeutic effect and appropriate course of recombinant human growth hormone (rhGH) in children with short stature (SGA). Methods: From December 2009 to December 2011, 88 children with STI short stature were divided into treatment group (34 cases) and control group (54 cases). The treatment group was given rhGH 0.15 U / (kg · d) treatment, and observed 6 months, 1 year, 1 year and 6 months, 2-year course of treatment of children with growth. Results: After 2 years of observation, 31 patients in the treatment group appeared to catch up with growth effectively, with an effective rate of 91.2%. Only 5 patients in the control group showed catch-up growth with an effective rate of 9.3% (χ2 = 57.92 P <0.01). There was no significant difference in the curative effect of rhGH between two courses (χ2 = 0.57, P> 0.05) ), The rest of the different treatment groups were significantly different between the efficacy (P <0.05). Conclusion: rhGH can effectively promote the growth of children with STI. In a dose of 0.15 U / kg per day, rhGH can make most children reach the normal height range of X-1SD-X at 1 year and 6 months 6-month course of treatment cost and benefit ratio is higher, is suitable for treatment.